Results 251 to 260 of about 7,770,494 (359)

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Effect of ayres sensory integration ^®-based occupational therapy intervention on sensory processing in a child with 4p trisomy and 10q monosomy: a case report. [PDF]

BMC Pediatr
Buğday T, Cemali M, Karaduman AA.
europepmc   +1 more source

Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 Variants in Warfarin Therapy

Therapeutic Drug Monitoring, 2015
Kaitlyn Shaw, U. Amstutz, R. Kim, L. Lesko, J. Turgeon, V. Michaud, Soomi Hwang, S. Ito, C. Ross, B. Carleton   +9 more
semanticscholar   +1 more source

Gene Therapy for Genetic Skin Disease [PDF]

Journal of Investigative Dermatology, 1998
openaire   +3 more sources

The rapidly growing landscape of RAS inhibitors: from selective allele blockade to broad inhibition strategies

Molecular Oncology, EarlyView.
RAS‐targeted therapies have become a clinical reality. Although promising results in patients have been achieved, there are still challenges ahead such as coping with drug resistance. Here we summarize selected RAS inhibitors targeting either individual KRAS mutant isoforms (KRASG12C, KRASG12D, KRASG12V) or exhibiting a wider inhibitory spectrum ...
Matthias Drosten, Mariano Barbacid
wiley   +1 more source

Editorial: Challenges and advances in primary antibody deficiencies diagnosis, treatment and follow-up. [PDF]

Front Pediatr
La Vecchia A, Baselli LA, Agostoni C, Dellepiane RM.   +3 more
europepmc   +1 more source

Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy.

Circulation Research, 2017
A. Marian, E. Braunwald
semanticscholar   +1 more source

A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications

Molecular Oncology, EarlyView.
Hypoxia reshapes tumour redox landscapes by altering compartmental ROS production (mitochondria, NOX, ER, peroxisomes). Accurate interpretation requires oxygen‐contextualised measurement (live biosensors, chemical probes, EPR, LC–MS) and awareness of artefacts (reoxygenation, probe specificity).
Lina Hacker, Elysia Sarsam, Stuart J. Conway, Ester M. Hammond   +3 more
wiley   +1 more source

Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies. [PDF]

Discov Oncol
Ikhtiar F, Jamal A, Bokhari SMSM.
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source